Evidence map›Paper›PMID 36364290›Full record

ArticleMolecules (Basel, Switzerland)2022

Synthesis of New 2,3-Dihydroindole Derivatives and Evaluation of Their Melatonin Receptor Binding Affinity.

Maria S Volkova, Alexander M Efremov, Elena N Bezsonova, Michael D Tsymliakov, Anita I Maksutova, Maria A Salykina, Sergey E Sosonyuk, Elena F Shevtsova, Natalia A Lozinskaya

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maria S VolkovaDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Alexander M EfremovDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Elena N BezsonovaDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Michael D TsymliakovDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Anita I MaksutovaDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Maria A SalykinaDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Sergey E SosonyukDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Elena F ShevtsovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences (IPAC RAS), 142432 Moscow, Russia.ORCID 0000-0003-2887-1185
Natalia A LozinskayaDepartment of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.

Funding

Russian Science Foundation 22-13-00228
6 · The paper itself

Abstract

2,3-Dihydroindoles are promising agents for the synthesis of new compounds with neuroprotective and antioxidant properties. Usually, these compounds are obtained by direct reduction of the corresponding indoles containing acceptor groups in the indole ring for its activation. In this work, we propose a synthetic strategy to obtain new 2,3-dihydroindole derivatives from the corresponding polyfunctional 2-oxindoles. Three methods were proposed for reduction of functional groups in the 2-oxindole and 2-chloroindole molecules using various boron hydrides. The possibility of chemoselective reduction of the nitrile group in the presence of an amide was shown. The proposed synthetic strategy can be used, for example, for the synthesis of new analogs of the endogenous hormone melatonin and other compounds with neuroprotective properties.

Indexed as

MelatoninAntioxidantsProtein BindingReceptors, MelatoninStructure-Activity RelationshipAntioxidantsMelatoninReceptors, Melatonin2,3-dihydroindole2-chloromelatonin2-oxindole reductionchemoselective reductionmelatoninnitrile reduction

Identifiers

PMID36364290
PMCPMC9655341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.